AOD-9604 mechanism research — the hGH lipolytic domain, receptor-independent signalling

The AOD-9604 parent guide answers what the fragment is, where it came from, and what the research-supply landscape looks like. This spoke goes a level deeper into the molecular pharmacology researchers actually argue about. AOD-9604 is the C-terminal fragment of human growth hormone — residues 177-191, carrying an N-terminal tyrosine, roughly 1,815 Da, held together by an internal disulphide bridge. Its published pharmacology is built almost entirely around adipocyte lipid metabolism. And the central puzzle, two decades into the research record, is not whether it acts on lipid metabolism but through which receptor— because the obvious candidates have been ruled out.

A fragment of a hormone, studied as a lipid-metabolism tool

To understand how AOD-9604 works you have to start with what it is a piece of. Human growth hormone is a 191-residue protein with several distinguishable activities folded into one molecule: the somatogenic activity that drives growth and IGF-1 production, an insulin-modulating activity, and a separate effect on lipid metabolism. The question the original researchers asked was whether those activities are separable — whether the lipid-metabolism action lives in a specific region of the sequence that could be detached from the rest.

AOD-9604 is the answer to that question rendered as a synthetic peptide. It corresponds to the C-terminal residues 177-191 of the hormone, with a tyrosine added at the N-terminus (originally to allow radiolabelling) and the native internal disulphide bridge preserved. So its pharmacology is not studied the way a small-molecule drug is studied; it is studied as a dissectionof the parent hormone — an attempt to find out which job the C-terminal end of growth hormone does on its own. The published record concentrates on one job: adipocyte lipid metabolism. The unresolved part — and the genuinely interesting part — is the receptor.

The lipolytic-domain concept

The foundational idea is that the lipid-metabolism activity of growth hormone is carried by a discrete structural region — a “lipolytic domain” — that can be reproduced synthetically and studied in isolation. Structure-activity work by Ng and colleagues established exactly this: the C-terminal fragment of human growth hormone retains the lipid-metabolism activity of the intact hormone while not carrying the somatogenic activity that drives growth and IGF-1 output [1].

That separation is the conceptual heart of the molecule. Intact growth hormone is a multifunctional protein; AOD-9604 is presented as the part of it that handles lipid metabolism, decoupled from the growth-promoting machinery. The same characterisation work also reported that the synthetic lipolytic domain did not adversely affect insulin sensitivity — an important point because the insulin-modulating activity of the full hormone is one of the activities the fragment was designed not to carry. In other words, the structure-activity case is not only that AOD-9604 keeps the lipid-metabolism action, but that it sheds the activities — somatogenic and insulin-disturbing — that come bundled with the intact hormone [1].

The whole premise is subtraction: take growth hormone, keep the lipid-metabolism activity, drop the growth and insulin-modulating activities. AOD-9604 is the C-terminal residue range that supposedly survives that subtraction.

Lipolysis comparable to hGH — but not via β3-adrenergic

The next question is how strong the retained lipid-metabolism action actually is, and through what local machinery it operates. Here the work of Heffernan and colleagues is the key reference. In adipose tissue, AOD-9604 stimulates lipolysis — the breakdown of stored triglyceride into free fatty acids and glycerol — at a magnitude comparable to that of intact human growth hormone [2]. That is a meaningful claim: the small C-terminal fragment reproduces the lipolytic effect of the full 191-residue hormone in this assay, which is the strongest single piece of evidence that the lipolytic-domain concept holds.

Just as important is what does not carry that effect. The classical adrenergic route into adipocyte lipolysis runs through β-adrenergic receptors, and the β3-adrenergic receptor in particular is a well-known adipose lipolysis switch. The Heffernan work reports that the lipolytic action of AOD-9604 is not mediated by the β3-adrenergic receptor [2]. So the fragment drives lipolysis comparable to growth hormone, but it is not simply borrowing the obvious adrenergic pathway to do it. That negative result is the first of two that, together, define the receptor puzzle.

Independent of the growth-hormone receptor

The second — and more striking — negative result concerns the receptor you would most expect a growth-hormone fragment to use: the growth-hormone receptor (GHR) itself. The intuitive hypothesis is that a piece of growth hormone exerts its effects by docking onto the same receptor as the whole hormone, just less efficiently. The data say otherwise. In receptor-binding assays, AOD-9604 does not compete for the growth-hormone receptor, and it does not produce the GH-receptor-mediated cell proliferation that intact growth hormone drives — yet it still produces its lipid-metabolism effects [3].

That combination is the crux of the mechanism. The fragment carries a clear lipid-metabolism action, but it does so without engaging the canonical receptor of its parent hormone. The effect and the obvious receptor are dissociated. This is direct evidence that AOD-9604 signals through a pathway distinct from canonical GHR signalling — the lipid-metabolism activity is real, but it is reaching the adipocyte by some route other than the growth-hormone receptor.

The same line of work also reports a consequence that follows naturally from the GHR independence: unlike intact human growth hormone, AOD-9604 is not diabetogenic — it does not produce the insulin and glucose disturbances that the full hormone can cause [3]. Because the fragment is not driving the GHR-mediated programme, it does not bring along the metabolic side of that programme either. That fits the lipolytic-domain story: the lipid-metabolism activity is retained, the GHR-linked activities — growth, proliferation, insulin/glucose disturbance — are not.

In-vitro metabolism and the metabolites

A separate strand of work asks a different question: not how the fragment signals, but what happens to the molecule itself once it is in a biological matrix. A validated analytical study by Cox and colleagues characterised the in-vitro metabolism of AOD-9604 using mass-spectrometry-based detection methods [4]. This is metabolism in the pharmacokinetic sense — the enzymatic breakdown of the peptide — and it matters for the mechanism story because it tells you which fragments of the fragment actually persist.

The study identified six metabolites of AOD-9604, among them one stable metabolite with the sequence CRSVEGSCG [4]. A stable metabolite is analytically valuable: it provides a durable marker that the compound was present, which is precisely why this work sits in the anti-doping literature. AOD-9604 is a peptide banned in sport by WADA, and the identification of a stable metabolite gives testing laboratories a reliable detection target. For a mechanism article, the relevance is narrower but real: the metabolism record shows the molecule is processed into a defined and characterisable set of products rather than vanishing without trace, and the persistence of CRSVEGSCG is the analytical anchor for that processing.

The open receptor question

Put the strands together and an unusual picture emerges. The lipid-metabolism action is reasonably well documented: lipolysis comparable to intact growth hormone in adipose tissue, framed by the lipolytic-domain structure-activity work that separates this activity from the somatogenic and insulin-modulating activities of the parent hormone. The metabolism is characterised down to a named stable metabolite. What is missing — conspicuously — is the receptor.

The negative results are documented and consistent: not the β3-adrenergic receptor, not the growth-hormone receptor. The positive identification — the actual receptor or signalling pathway that carries the lipid-metabolism effect — is not. For a compound that has been in research circulation for more than two decades, that is an unusual gap. The effect is replicated; the mechanism of action, in the strict sense of the molecular target it engages, remains an open question.

The lipid-metabolism action is documented. The metabolites are characterised. The receptor is not identified. Two decades in, the most basic mechanistic question — what does it bind? — is still unanswered in the peer-reviewed record.

It is worth stating plainly what this does and does not mean. The mechanism research describes a lipid-metabolism action in cell-based and animal-model systems and a defined receptor-independence from two obvious candidates. It does not establish a human clinical effect of any kind. AOD-9604 has never been approved as a medicine by the FDA, EMA, or the UAE Ministry of Health; a food-ingredient GRAS classification is not a medicinal approval. Nothing here describes treating, preventing, or modifying any condition. This is research education, not medical advice.

Related reading in the AOD-9604 cluster

For what the fragment is, the Monash origin, the development history, and the UAE research-supply landscape, read the AOD-9604 parent guide. For where the evidence and regulatory record actually stand, see AOD-9604 evidence and regulatory status. For handling and study-design considerations, see AOD-9604 dosing research protocols. Overview: the research compounds in the UAE hub, and the AOD-9604 5 mg research-consultation page.

Further reading

Peer-reviewed citations used inline:

• [1] Ng et al. 2000. Metabolic characterisation of the synthetic lipolytic domain (AOD-9604) of human growth hormone — the C-terminal fragment carries the lipid-metabolism activity of the parent hormone while lacking its somatogenic activity, with no adverse effect on insulin sensitivity.
• [2] Heffernan et al. 2001. Lipolysis in adipose tissue comparable to intact human growth hormone, and not mediated by the β3-adrenergic receptor.
• [3] Heffernan et al. 2001. Receptor-binding and cell-proliferation assays — AOD-9604 does not compete for the growth-hormone receptor and does not drive GH-receptor-mediated proliferation, evidence of a distinct signalling pathway; not diabetogenic.
• [4] Cox et al. — Drug Test Anal 2014. In-vitro metabolism and analytical detection of AOD9604 — six metabolites identified including the stable metabolite CRSVEGSCG; the compound is banned in sport by WADA.

Last reviewed 12 June 2026. AOD-9604 is a research-grade peptide, not an approved medicine in any major regulatory jurisdiction; this article is research education and not medical advice. Wellness Labs supplies AOD-9604 as research-grade lyophilised powder for non-clinical investigation. Editorial inbox: info@uaewellnesslab.com.